

Special Issue

Role of Macrophages and Gut Microbiota in Liver Diseases

Message from the Guest Editor

This Special Issue aims to explore the intricate interplay between macrophages and gut microbiota, elucidating their pivotal roles in the landscape of liver diseases. Unveiling the dynamic relationship between these two entities is very important to understand the underlying mechanisms driving liver pathophysiology. Contributions to this Special Issue are invited to explore their collective impact on disease initiation, progression, and resolution. This Special Issue seeks to assemble cutting-edge research that dissects the molecular dialogues between macrophages and the gut microbiota, providing insights into therapeutic interventions and potential targets for liver diseases. The comprehensive exploration of this dynamic interplay is anticipated to enrich our understanding of liver pathologies and inspire novel avenues for therapeutic advancements. Authors are invited to contribute their latest findings to foster a nuanced understanding of the intricate relationship between macrophages, gut microbiota, and liver diseases.

- macrophages
- gut microbiota
- liver diseases
- immune response
- inflammation
- fibrosis
- microbial dysbiosis

Guest Editor

Prof. Dr. Yoshinori Nagai

Department of Pharmaceutical Engineering, Faculty of Engineering,
Toyama Prefectural University, Toyama, Japan

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/196606

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).